ArticleCirculation2013
Using benefit-based tailored treatment to improve the use of antihypertensive medications.
Article in Circulation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data.PLoS medicine · 2018Pooled it
- Individualized Net Benefit of Intensive Blood Pressure Lowering Among Community-Dwelling Older Adults in SPRINT.Journal of the American Geriatrics Society · 2025Trial
- Effectiveness of blood pressure-lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).Journal of clinical hypertension (Greenwich, Conn.) · 2019Trial
- Trial
- Effect of Population-Level Blood Pressure Treatment Strategies on Cardiovascular and Cognitive Outcomes.Circulation. Cardiovascular quality and outcomes · 2024Article
- Development and validation of the Michigan Chronic Disease Simulation Model (MICROSIM).PloS one · 2024Article
- Estimated Population Health Benefits of Intensive Systolic Blood Pressure Treatment Among SPRINT-Eligible US Adults.American journal of hypertension · 2023Article
- Application of ensemble machine learning algorithms on lifestyle factors and wearables for cardiovascular risk prediction.Scientific reports · 2022Article
- Cumulative exposure to elevated blood pressure better predicts cardiovascular disease risk in rural Chinese adults.Frontiers in public health · 2022Article
- Understanding providers' attitudes and key concerns toward incorporating CVD risk prediction into clinical practice: a qualitative study.BMC health services research · 2021Article
- Optimal cholesterol treatment plans and genetic testing strategies for cardiovascular diseases.Health care management science · 2021Article
- Derivation and Application of a Tool to Estimate Benefits From Multiple Therapies That Reduce Recurrent Stroke Risk.Stroke · 2020Article
- Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study.Lancet (London, England) · 2019Article
- Clinic-Based Strategies to Reach United States Million Hearts 2022 Blood Pressure Control Goals.Circulation. Cardiovascular quality and outcomes · 2019Article
- Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support.Medical decision making : an international journal of the Society for Medical Decision Making · 2019Article
- Potential Cardiovascular Disease Events Prevented with Adoption of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline.Circulation · 2019Article
- Matching Microsimulation Risk Factor Correlations to Cross-sectional Data: The Shortest Distance Method.Medical decision making : an international journal of the Society for Medical Decision Making · 2018Article
- Designing for Clinical Change: Creating an Intervention to Implement New Statin Guidelines in a Primary Care Clinic.JMIR human factors · 2018Article
- Potential U.S. Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline.Journal of the American College of Cardiology · 2018Article
- Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
backgroundCurrent guidelines for prescribing antihypertensive medications focus on reaching specific blood pressure targets. We sought to determine whether antihypertensive medications could be used more effectively by a treatment strategy based on tailored estimates of cardiovascular disease events prevented. METHODS AND
resultsWe developed a nationally representative sample of American adults aged 30 to 85 years with no history of myocardial infarction, stroke, or severe congestive heart failure using the National Health and Nutrition Examination Survey III. We then created a simulation model to estimate the effects of 5 years of treatment with treat-to-target (treatment to specific blood pressure goals) and benefit-based tailored treatment (treatment based on estimated cardiovascular disease event reduction) approaches to antihypertensive medication management. All effect size estimates were derived directly from meta-analyses of randomized trials. We found that 55% of the overall population of 176 million Americans would be treated identically under the 2 treatment approaches. Benefit-based tailored treatment would prevent 900 000 more cardiovascular disease events and save 2.8 million more quality-adjusted life-years, despite using 6% fewer medications over 5 years. In the 45% of the population treated differently by the strategies, benefit-based tailored treatment would save 159 quality-adjusted life-years per 1000 treated versus 74 quality-adjusted life-years per 1000 treated by the treat-to-target approach. The findings were robust to sensitivity analyses.
conclusionsWe found that benefit-based tailored treatment was both more effective and required less antihypertensive medication than current guidelines based on treating to specific blood pressure goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.